Diffusion and Launch Sequencing of Cell and Gene Therapies across the USA, UK, Europe, Canada and Australia

This poster presents a global analysis of how FDA-approved cell and gene therapies (CGTs) are progressing through regulatory and HTA milestones in the USA, UK, Europe, Canada, and Australia. The study highlights how firm size, therapeutic area, and evidence type impact the likelihood of global uptake, revealing fragmented access patterns and slower diffusion in the post-Brexit UK.

Notably, only four CGTs received positive HTA recommendations in all markets studied. Oncology remains the leading therapeutic area, and large firms dominate in multi-market launches. Presented at ISPOR 2025 in Montreal, this research offers key insights into global market access strategy for advanced therapies.

Please click here to download the poster
‍
Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!